Literature DB >> 18070319

Azithromycin-induced torsade de pointes.

Bien-Hsien Huang1, Chi-Hua Wu, Chih-Ping Hsia, Chung Yin Chen.   

Abstract

Although erythromycin frequently induces long QT interval and torsade de pointes, the newer drug, azithromycin, has rarely been reported to be associated with torsade de pointes. We report here the occurrence of a significant typical QT prolongation within a few hours after taking azithromycin which lead to torsade de pointes.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18070319     DOI： 10.1111/j.1540-8159.2007.00912.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN： 0147-8389            Impact factor:   1.976


  41 in total

1.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

2.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

Review 3.  Gastroparesis: current diagnostic challenges and management considerations.

Authors:  Shamaila Waseem; Baharak Moshiree; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-01-07       Impact factor: 5.742

4.  Should azithromycin no longer be considered a drug of choice for community-acquired pneumonia because of its potential to cause cardiovascular death?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2013-09

5.  Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.

Authors:  Mai H Trac; Eric McArthur; Racquel Jandoc; Stephanie N Dixon; Danielle M Nash; Daniel G Hackam; Amit X Garg
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

Review 6.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

7.  Use of azithromycin and risk of ventricular arrhythmia.

Authors:  Gianluca Trifirò; Maria de Ridder; Janet Sultana; Alessandro Oteri; Peter Rijnbeek; Serena Pecchioli; Giampiero Mazzaglia; Irene Bezemer; Edeltraut Garbe; Tania Schink; Elisabetta Poluzzi; Trine Frøslev; Mariam Molokhia; Igor Diemberger; Miriam C J M Sturkenboom
Journal:  CMAJ       Date:  2017-04-18       Impact factor: 8.262

8.  Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.

Authors:  Gowtham A Rao; Joshua R Mann; Azza Shoaibi; Charles Lee Bennett; Georges Nahhas; S Scott Sutton; Sony Jacob; Scott M Strayer
Journal:  Ann Fam Med       Date:  2014 Mar-Apr       Impact factor: 5.166

Review 9.  Exposure to antibacterial agents with QT liability in 14 European countries: trends over an 8-year period.

Authors:  Emanuel Raschi; Elisabetta Poluzzi; Chiara Zuliani; Arno Muller; Herman Goossens; Fabrizio De Ponti
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

Review 10.  Cardiac risks associated with antibiotics: azithromycin and levofloxacin.

Authors:  Zhiqiang Kevin Lu; Jing Yuan; Minghui Li; S Scott Sutton; Gowtham A Rao; Sony Jacob; Charles L Bennett
Journal:  Expert Opin Drug Saf       Date:  2014-12-10       Impact factor: 4.250
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.